Alzheimer's disease is a devastating neurodegenerative disease eventually leading to dementia. An effective treatment does not yet exist. Here we show that oral application of the compound anle138b restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology. At the mechanistic level, we provide evidence that anle138b blocks the activity of conducting Ab pores without changing the membrane embedded A beta-oligomer structure. In conclusion, our data suggest that anle138b is a novel and promising compound to treat AD-related pathology that should be investigated further.

A database, AmyProt, was developed that collated details of 32 human amyloid proteins associated with disease and 488 associated mutations and polymorphisms, of which 316 are classified as amyloid. A detailed profile of the mutations was developed in terms of location within domains and secondary structures of the proteins and functional effects of the mutations. The data was used to test the hypothesis that mutations enhance amyloidosis in human amyloid proteins have distinctive characteristics, in terms of specific location within proteins and physico-chemical characteristics, which differentiate them from non-amyloid forming polymorphisms in amyloid proteins and from disease mutations and polymorphisms in non-amyloid disease linked proteins. The aim was to use these characteristics to train a prediction algorithm for amyloid mutations that will provide a more accurate prediction than current general disease prediction tools and amyloid prediction tools that focus on aggregating regions. 66 location specific features and changes upon mutation of 366 amino acids propensities, derived from the amino acid index database AAindex, were analysed. A significant proportion of mutations were located with aggregating regions, however the majority of mutations were not associated with these regions. An analysis of motifs showed that amyloid mutations had a significant association with transmembrane helix motifs such as GxxxG. Statistical analysis of substitutions mutations, using substitution matrices, showed that amyloid mutations have a decrease in α-helix propensity and overall secondary structure propensity compared to the disease mutations and disease and amyloid polymorphisms. Machine learning was used to reduce the large set of features to a set of 18 features. These included location near transmembrane helices, secondary structure features; transmembrane and extracellular domains and 4 amino acid propensities: knowledge-based membrane propensity scale from 3D helix; α-helix propensity; partition coefficient; normalized frequency of coil. The AmyProt mutations and non-amyloid polymorphisms were used to train and test the novel amyloid mutation prediction tool, AmyPred, the first tool developed purely to predict amyloid mutations. AmyPred predicts the amyloidogenicity of mutations as a consensus by majority vote (CMV) and mean probability (CMP) of 5 classifiers. Validation of AmyPred with 27 amyloid mutations and 20 non-amyloid mutations from APP, Tau and TTR proteins, gave classification accuracies of 0.7/0.71 (CMV/CMP) and with an MCC of 0.4 (CMV) and 0.41 (CMP). AmyPred out performed other tools such as SIFT (0.37) and PolyPhen (0.36) and the amyloid consensus prediction tool, MetAmyl (0.13). Finally, AmyPred was used to analyse p53 mutations to characterize amyloid and non-amyloid mutations within this protein.

There is an urgent need for the development of new therapeutic strategies for Alzheimer's disease (AD). The dual-specificity tyrosine phosphorylation-regulated kinase-1A (Dyrk1a) is a protein kinase that phosphorylates the amyloid precursor protein (APP) and tau and thus represents a link between two key proteins involved in AD pathogenesis. Furthermore, Dyrk1a is upregulated in postmortem human brains, and high levels of Dyrk1a are associated with mental retardation. Here, we sought to determine the effects of Dyrk1 inhibition on AD-like pathology developed by 3xTg-AD mice, a widely used animal model of AD. We dosed 10-month-old 3xTg-AD and nontransgenic (NonTg) mice with a Dyrk1 inhibitor (Dyrk1-inh) or vehicle for eight weeks. During the last three weeks of treatment, we tested the mice in a battery of behavioral tests. The brains were then analyzed for the pathological markers of AD. We found that chronic Dyrk1 inhibition reversed cognitive deficits in 3xTg-AD mice. These effects were associated with a reduction in amyloid-beta (Ab) and tau pathology. Mechanistically, Dyrk1 inhibition reduced APP and insoluble tau phosphorylation. The reduction in APP phosphorylation increased its turnover and decreased Ab levels. These results suggest that targeting Dyrk1 could represent a new viable therapeutic approach for AD.

The deposition of amyloid in the central nervous system is associated with prevalent neurological disorders such as Alzheimer's and Parkinson's disease. This thesis studies the mechanisms and prevention of amyloid formation in vitro. We specifically focus on Parkinson's disease associated α-synuclein (α-syn). Using novel labeling methods we introduce NMR observable labels onto lysosomal protein glucocerebrosidase (GCase), a leading cause of Parkinson's disease. By introducing NMR active labels we are able to study GCase dynamics and screen potential drug therapeutics (chapter 3). Furthermore, we analyze the three way interaction between GCase, α-syn and lipids. We conclude that GCase is able to effectively chaperone α-syn under lysosomal conditions, both preventing amyloidogenesis and destabilizing mature amyloid fibrils (chapter 4). Additionally, a model chaperone-aggregate system is investigated to gain insight into the mechanisms of small heat shock protein chaperoning, and how such mechanisms prevent aggregation (chapter 5). Finally, a high resolution crystal structure of RNA editing enzyme Cid1 is presented, whilst not directly linked to aggregation, many of the techniques used in this thesis were first developed on Cid1 (chapter 7). Together, we utilize NMR, X-ray crystallography, electron microscopy and native mass spectrometry to elucidate aspects of protein aggregation mechanisms and prevention.

Metal ions are ubiquitously found in all living systems and play vital roles in supporting life forms by performing an array of biological activities. Such biological activities include binding and transforming organic molecules, and also acting as active centers and cofactors for catalysis of various acid-base and redox reactions in biological system. The main focus in bioinorganic chemistry is to elucidate the structural and functional roles of metals in biological systems. Among all transition metal ions, Cu2+ and Fe3+ are especially versatile and important due to their abilities to go through redox efficiently. This dissertation can be divided into four main chapters. The bioinorganic chemistry of Cu- and Fe-containing proteins were briefly discussed in Chapter one. The next chapter focuses on bacitracin, a cyclic peptide-based antibiotic produced by soil bacteria Bacillus subtilis. Bacitracin is a metalloantibiotics that can coordinate with many transition metal ions and exhibit different biological activities. In the first part of Chapter two, the aim is to explore the chemicals interactions in soil micro-ecology by investigating the interactions of different flavonoids and Cu(II)-bacitracin complex. The second part of chapter two demonstrated the binding and oxidation activity of iron(III)-bacitracin. Metal-mediated oxidative stress plays a crucial role in the development of different neurodegenerative diseases. In chapter 3, various synthetic and natural compounds were used to inhibit the oxidation chemistry mediated by Cu(II)-beta-amyloid complex associated with Alzheimer’s disease. Many proteins incorporate copper ions at their active sites for different functions, and among all of the chemistry copper-containing-proteins can perform, one of the most interesting aspect is the ability to bind and activate O2. Therefore, the biomimetic of two different Cu(II) complexes were investigated. In all studies, a combination of kinetic and different spectroscopic methods (UV-vis, NMR and resonance Raman spectroscopy) were used to study their metal binding and activity.

The amyloid beta peptide (Aβ) plays an important role in Alzheimer’s disease (AD). Increasing evidence suggest that overactivation of extrasynaptic N-methyl-D-aspartate receptors (NMDARs) mediate Aβ-induced excitotoxicity. In serine racemase knockout (SRKO) mice with significantly depleted D-serine levels, Aβ-induced excitotoxicity is attenuated. Using SRKO mice, this thesis attempts to determine the effects of Aβ on synaptic and extrasynaptic NMDAR function, and how D-serine can alter these Aβ- mediated effects. In CA1 pyramidal neurons, Aβ significantly depresses evoked synaptic NMDAR excitatory postsynaptic currents (EPSCs), and this effect is even greater in SRKO mice. The same effect was also observed on isolated evoked extrasynaptic NMDAR currents. During synaptic NMDAR current recordings, Aβ potentiated the holding current in wild type (WT) mice, but not SRKO mice, suggesting an increase in extrasynaptic NMDAR activation in WT, but not in SRKO mice. SRKO mice attenuated Aβ-induced holding current shift and had reduced basal tonic NMDAR activation. These data, along with evidence from previous studies in the literature, suggest that low levels of D-serine can alter NMDAR function in the presence of Aβ. These findings provide insight for future experiments in exploring the importance of D-serine in AD.

Alzheimer's disease (AD) is an incurable disease characterized by a slow, progressive decline in cognitive functions as well as the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles. Interestingly, two thirds of AD patients are women who have a faster disease progression. Despite this clinical profile, sex differences in AD pathophysiology are largely ignored at the basic and clinical levels. Current therapies provide only mild to moderate improvement in patient symptoms. There is, therefore, an urgent need to expand our understanding of the underlying pathophysiology of AD, and to obtain alternative hypotheses and therapeutics. A recent and promising development involves the sigma-1 receptor (Sig1R), a protein regulated by steroid hormones, which has been implicated in AD. Most interestingly, Sig1R agonists have been shown to ameliorate cognitive deficits in an AD mouse model. Here, we investigated the role of Sig1Rs in an Aβ25-35-infusion mouse model of AD, using behavioural paradigms. Previous studies employing this model have demonstrated Aβ-induced impairments in learning and memory in young male rodents, while no work has been done on females. We examined cognitive function following Aβ25-35 infusion in wild-type and knock-out Sig1R adult male and female mice using the Morris water maze, spontaneous alternation in the Y-maze, and forced alternation in the Y-maze tasks. Overall, the data unexpectedly shows that genotype, Aβ25-35-treatment, and sex had no effect on cognitive functions. These results suggest that additional efforts are required to obtain a working Aβ25-35-infusion model in our Sig1R mice and behavioural tasks. Future experiments will hopefully shed some light on the link between Sig1Rs and AD, which could lead to the development of therapeutics and disease prevention.

Alzheimer’s disease (AD) is a devastating neurodegenerative disease that affect millions of people worldwide. Aggregation of Amyloid-β (Aβ) monomers create toxic oligomers that can interact with cellular membranes and disturb cellular functions, resulting in cell death and neurological dysfunction. Increased levels of oxidative stress have been shown in the brains of AD patients, something that besides the obvious cell and tissue toxicity, also favors the amyloidogenic pathway and generates more Aβ monomers. Here we show that Edaravone, a free radical scavenger can affect the aggregation rate of different lengths of Aβ. We show that Aβ-40 that is more commonly found in vivo aggregates faster with addition of Edaravone, while Aβ-42 aggregates slower or not at all. These findings add up to previous findings where free radical scavengers and antioxidants such as Edaravone have been suggested as a potential treatment in Alzheimer’s disease.

L’étude des interactions moléculaires au niveau des membranes biologiques est un enjeu capital pour le développement et le screening de nouvelles molécules médicamenteuses. La MA est la forme de démence sénile la plus répandue dans le monde et représente le principal problème socioéconomique en matière de soins de santé. L'apparition et la progression de cette maladie neurodégénérative sont associées à l'agrégation du peptide Aβ.Une stratégie thérapeutique contre la MA consiste à développer des molécules capables d'interférer à des étapes spécifiques de l’agrégation du peptide. Pour les identifier, des méthodes expérimentales sont nécessaires pour suivre et caractériser le peptide Aβ au cours de son processus de fibrillation. Ces méthodes doivent être suffisamment simples pour rester compatibles avec une démarche de drug discovery. Dans le présent travail de thèse, nous avons proposé de combiner des méthodes expérimentales pour permettre une caractérisation multiparamétrique de modulateurs potentiels de la fibrillation du peptide Aβ1-42, en y intégrant des liposomes de composition définie, comme membranes neuronales biomimétiques. Il est en effet établi que les lipides neuronaux sont un facteur important dans la formation des fibres amyloïdes et leur toxicité. Les liposomes ont été formulés par la méthode de réhydratation de film lipidique, et leurs propriétés physico-chimiques caractérisées par RMN, DLS, potentiel ζ.La détermination expérimentale du coefficient de partage de composés d’intérêt a pu être réalisée par spectrophotométrie, y compris de façon originale, par fluorescence, en utilisant ces liposomes, dans des tests miniaturisés. Des études cinétiques de l’agrégation du peptide Aβ1-42 ont été effectuées en présence de liposomes. La fluorescence de la ThT a été mesurée pour suivre la voie de la fibrillation du peptide Aβ, utilisé dans sa forme sauvage ou celle d’un mutant oligomérique, l’oG37C. Une analyse de fuite d’un fluorophore à partir des liposomes, appuyée par des mesures en DLS, a été réalisée afin d'évaluer l'impact des interactions entre le peptide et les membranes pour prévoir tout effet de déstabilisation. Les fibres toxiques formées par Aβ étant principalement organisées en feuillets β, les données ont été corrélées à l'analyse de la structure secondaire du peptide par spectroscopie ATR-FTIR. Après avoir mis en œuvre cette approche sur différentes molécules modèles et un hit d’intérêt potentiel dans le traitement de la MA, l’ensemble de ce travail a abouti à un test multiparamétrique permettant la caractérisation de l’interactome molécules/Aβ/membranes et la discrimination de modulateurs de l'agrégation du peptide Aβ1-42. Cette approche pourra être avantageusement transposée à d'autres maladies amyloïdes. / The study of molecular interactions at the level of biological membranes is a key issue for the screening and the development of new drugs. Alzheimer's disease (AD) is the most common form of senile dementia in the world and is the leading socio-economic problem in health care. The appearance and progression of this neurodegenerative disease are associated with the aggregation of the amyloid-β peptide (Aβ). A therapeutic strategy against AD consists in the development of molecules able to interfere with specific steps of Aβ aggregation. To identify such compounds, experimental methods are required to monitor and characterize the Aβ peptide during its fibrillation process. These methods must be simple enough to remain compatible with drug discovery. In this PhD project, we have proposed to combine experimental methods to allow a multiparametric characterization of potential Aβ1-42 fibrillation modulators, by integrating liposomes of defined composition as biomimetic neuronal membranes. It is indeed established that neuronal lipids are an important factor in the formation of amyloid fibers and their toxicity. The liposomes were formulated by the lipid film rehydration method, and their physicochemical properties characterized by NMR, DLS, ζ potential. The experimental determination of the compounds partition coefficient could be carried out by spectrophotometry, including in an original way, by fluorescence, these liposomes, in miniaturized tests. Kinetic studies of Aβ1-42 peptide aggregation were performed in the presence of liposomes.The ThT fluorescence was monitored to follow the Aβ peptide fibrillation pathway, used in its wild form or with an oligomeric mutant, oG37C. A fluorophore leakage analysis from liposomes, supported by DLS measurements, was performed to evaluate the impact of peptide/membranes interactions to predict any destabilization effects. The toxic fibers formed by Aβ being mainly organized in β-sheets, the data were correlated with the analysis of the peptide secondary structure by ATR-FTIR spectroscopy. After the implementation of this approach on different model molecules and a hit of potential interest in the AD treatment, all of this work has resulted in a multiparametric test allowing the molecules/Aβ/membranes interactome characterization and the discrimination of Aβ1-42 peptide aggregation modulators. This approach may be advantageously transposed to other amyloid diseases.

In recent years, lower-chlorinated, airborne congeners of polychlorinated biphenyls (PCBs) have evolved as an emerging class of potentially hazardous environmental contaminants. Previous work has demonstrated that sulfation is a major metabolic pathway for these PCBs in vitro and in vivo; however, their metabolic fate and toxicities have not been explored. Hypothyroxinemia is among the most prevalent adverse health effects associated with PCB exposure in human populations and is an assumed cause of a variety of neurodevelopmental effects observed in infants following prenatal PCB exposure. The displacement of L-thyroxine (T4) from binding sites on transthyretin (TTR), a major T4 transport protein and trans-placental carrier of thyroid hormones, is thought to be a significant contributing factor in PCB-induced hypothyroxinemia. Structural similarities between sulfated metabolites of PCBs and T4 led to the central hypothesis that PCB sulfates are bioactive metabolites that exhibit high affinity binding to T4 binding sites on human TTR. An examination of the ability of six lower-chlorinated PCB sulfates to bind to human TTR in vitro, as well as subsequent computational modeling, revealed that these compounds interact with the high-affinity binding site in a non-covalent manner and with affinities comparable to T4. Corroborating evidence for the binding of PCB sulfates stems from their ability to inhibit the formation of TTR amyloid fibrils through stabilization of the protein's native conformation. Fibrillar TTR aggregates are the cause of amyloidoses like senile systemic amyloidosis, familial amyloid polyneuropathy and familial amyloid cardiomyopathy. All PCB sulfates examined were effective inhibitors of TTR fibrillogenesis with equal or higher efficiencies than some of the best previously described inhibitors. In vivo exposure of male Sprague-Dawley rats to a model PCB sulfate, 4-PCB 11 sulfate, resulted in rapid and widespread distribution of the metabolite to various organs, including the brain. Consequently, there is a strong indication for a potential role of PCB sulfates in thyroid disruption and inter-tissue transport of PCBs, and the binding of PCB sulfates to TTR may also provide structural information for improved design of anti-amyloid therapeutics. To date there are no analytical procedures for the quantification of PCB sulfates available, and exposure levels in human populations remain unknown. This study provides, for the first time, evidence that PCB sulfates, if present in human serum samples, are not extracted by current standard protocols for the analysis of PCBs and their metabolites. Consequently, PCB sulfates may have been overlooked in the past decades resulting in potential underestimation of total PCB exposure levels in exposed populations. Based on this finding, an efficient approach for the quantitative extraction of PCB sulfates from a variety of biological samples was developed. This procedure, coupled with quantitative mass spectrometry, has been validated for the future screening of human serum samples, and it was successfully applied to determine the tissue distribution and elimination profile of 4-PCB 11 sulfate in male Sprague-Dawley rats.